Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

THERMO FISHER SCIENTIFIC

(TMO)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Thermo Fisher Scientific : Termo Fisher Scientific Expands Hematology Oncology NGS Portfolio

07/20/2021 | 08:28am EDT

CARLSBAD, Calif. - Thermo Fisher Scientific announced a new suite of Ion Torrent Oncomine immune repertoire assays designed to detect potentially malignant clones of T-cells and B-cells, which play a key role in the immune response system*. Using proprietary Ion AmpliSeq technology, the new pan-clonality assays target multiple parts of the B- and T-cell immune receptors using a single reaction with ultra-high sensitivity, thereby increasing the probability of malignant clone detection and decreasing the time to results.

Detection of distinct receptor DNA sequences can inform diagnostic, prognostic and therapy development studies in the progression of lymphoid cancers including leukemias, lymphomas and diseases such as multiple myeloma. Using next-generation sequencing (NGS) technology, detection sensitivity can be increased compared to traditional testing methods such as flow cytometry or qPCR.

'Every three minutes, one person in the U.S. is diagnosed with a blood cancer. Genomic testing can make a significant impact on researching and understanding these cancers - but we need to bring more testing to in-house laboratories where results can be made available quickly to healthcare professionals,' said Garret Hampton, president of clinical next-generation sequencing at Thermo Fisher Scientific. 'The new Oncomine immune repertoire assays unlock the power of NGS to help researchers rapidly obtain a tremendous amount of insight about a lymphoid cancer sample, including its prevalence and an understanding of how it is evolving.'

One of the challenges of current NGS-based immune repertoire analysis has been the need to run multiple secondary tests due to the high test-failure rates of a typical single NGS assay. The new Oncomine pan-clonality assays overcome this challenge by uniquely targeting multiple parts of the receptor to reduce the need for secondary tests and increase the probability that a single assay can detect a potentially malignant clone.

'With the ability to sequence multiple targets in a single reaction, our team can now get much more information from one assay when compared to single-target NGS tests,' said Dr. John DeCoteau, medical director, University of Saskatchewan, Advanced Diagnostic Research Laboratory. 'Using the Oncomine BCR Pan-Clonality Assay, we were able to achieve a positive clonality detection rate of 93 percent in a cohort of multiple myeloma samples, without the need for secondary testing. That provides a remarkable improvement for laboratory efficiency and allows us to get results faster.'

Thermo Fisher's new suite of immune repertoire assays are available on the Ion GeneStudio S5 System and feature integrated analysis and data visualization tools that simplify the interpretation of results for laboratories and healthcare professionals.

For more information on these assays, please visit oncomine.com/clonality.

For Research Use Only. Not for use in diagnostic procedures.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon. For more information, please visit www.thermofisher.com.

Contact:

Media

Mauricio Minotta

Phone: 760-805-5266

Email: mauricio.minotta@thermofisher.com

Jessika Parry

Phone: 419-266-4016

Email: jparry@greenough.biz

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc. (NYSE: TMO) is the world leader in serving science, with annual revenue exceeding $30 billion. Our Mission is to enable our customers to make the world healthier, cleaner and safer. Whether our customers are accelerating life sciences research, solving complex analytical challenges, improving patient diagnostics and therapies or increasing productivity in their laboratories, we are here to support them. Our global team of more than 80,000 colleagues delivers an unrivaled combination of innovative technologies, purchasing convenience and pharmaceutical services through our industry-leading brands, including Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, Unity Lab Services and Patheon.

(C) 2021 Electronic News Publishing, source ENP Newswire

All news about THERMO FISHER SCIENTIFIC
10:36aGLOBAL MARKETS LIVE : Daimler, GeNeuro, Nike, Thermo Fischer...
08:24aTHERMO FISHER SCIENTIFIC : First Net Zero Mass Spectrometer Launched to Support Greener Fu..
AQ
09/23THERMO FISHER SCIENTIFIC : Sets $3 Billion Share Buyback Program
MT
09/23THERMO FISHER SCIENTIFIC : Authorizes $3 Billion of Share Repurchases
PR
09/23Thermo Fisher Scientific Inc. announces an Equity Buyback for $3,000 million worth of i..
CI
09/23Tranche Update on Thermo Fisher Scientific Inc.'s Equity Buyback Plan announced on Nove..
CI
09/23Thermo Fisher Scientific Announces First Net Zero Mass Spectrometer Launched to Support..
CI
09/23THERMO FISHER SCIENTIFIC : Cowen Adjusts Price Target on Thermo Fisher Scientific to $655 ..
MT
09/23Thermo Fisher Scientific Inc.'s Equity Buyback announced on November 5, 2020, has expir..
CI
09/23Thermo Fisher Scientific Inc. authorizes a Buyback Plan.
CI
More news
Analyst Recommendations on THERMO FISHER SCIENTIFIC
More recommendations
Financials (USD)
Sales 2021 36 019 M - -
Net income 2021 7 158 M - -
Net Debt 2021 17 275 M - -
P/E ratio 2021 33,5x
Yield 2021 0,16%
Capitalization 240 B 240 B -
EV / Sales 2021 7,14x
EV / Sales 2022 6,33x
Nbr of Employees 80 000
Free-Float 89,6%
Chart THERMO FISHER SCIENTIFIC
Duration : Period :
Thermo Fisher Scientific Technical Analysis Chart | TMO | US8835561023 | MarketScreener
Technical analysis trends THERMO FISHER SCIENTIFIC
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 22
Last Close Price 608,23 $
Average target price 630,53 $
Spread / Average Target 3,67%
EPS Revisions
Managers and Directors
Marc N. Casper Chairman, President & Chief Executive Officer
Stephen Williamson Chief Financial Officer & Senior Vice President
Ryan Snyder Chief Information Officer & Senior Vice President
Alan B. Sachs Chief Medical Officer
Karen E. Nelson Chief Scientific Officer
Sector and Competitors